Sign In
Buy MNKD
$3.36
-0.0700 (-2.04%)
At Close: Jun 03, 2026
MannKind (MNKD) Q4 Earnings and Revenues Surpass Estimates
06:36pm, Tuesday, 27'th Feb 2024
MannKind (MNKD) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.07 per share a year ago.
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
04:00pm, Tuesday, 27'th Feb 2024
2023 Total revenues of $199M; +99% vs. 2022 4Q 2023 Total revenues of $58M; +62% vs.
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
06:00am, Tuesday, 20'th Feb 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 fourth quarter and full year financial results and its manageme
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
06:05am, Thursday, 15'th Feb 2024
Reached enrollment goal of 305 patients living with Type 1 or Type 2 diabetes Primary endpoint analysis expected in 4Q 2024 Data dissemination and FDA submission expected in 2025 DANBURY, Conn. and WE
MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
07:49pm, Wednesday, 14'th Feb 2024
MannKind sold a 10% stake in Tyvaso DPI for $150 million upfront, with an additional $50 million possible, indicating the potential value of the remaining 9% to be upwards of $1.8 billion. Liquidia's
Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices
10:49pm, Monday, 12'th Feb 2024
Liquidia's stock has increased in value by 209.32% since June 2022. Liquidia's PAH drug, Yutrepia, is expected to launch in the first or second quarter of 2024, potentially leading to profitability. L
3 Biotech Stocks to Sell in January Before They Crash and Burn
05:29pm, Thursday, 25'th Jan 2024
The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as compa
MannKind in royalty agreement with Sagard Healthcare for Tyvaso DPI
06:19am, Tuesday, 02'nd Jan 2024
MannKind Corp. MNKD, -1.62% said Tuesday it has entered a royalty agreement with Sagard Healthcare under which the latter will receive 1% of royalty sales of Tyvaso DPI inhalation powder for up to $20
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
06:00am, Thursday, 28'th Dec 2023
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of inhaled therapeutic pro
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
06:47pm, Tuesday, 07'th Nov 2023
While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics comp
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
04:00pm, Tuesday, 31'st Oct 2023
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 third quarter financial results and year to date financial resu
Tyvaso DPI Is Breathing New Life Into MannKind's Balance Sheet (Rating Upgrade)
12:04am, Wednesday, 18'th Oct 2023
Tyvaso DPI, a collaboration with United Therapeutics, diversifies MannKind's revenue streams and leverages its proprietary Technosphere technology, bolstering long-term prospects. While Afrezza faces
MannKind Corporation Announces Participation at Upcoming Conferences
06:00am, Tuesday, 05'th Sep 2023
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic p
3 Biotech Stocks to Sell in August Before They Crash and Burn
12:44pm, Monday, 14'th Aug 2023
Investors who've dipped their toe into the waters of biotech stocks know that the chances of these stocks crashing and burning is certainly higher than with most sectors. Failure is incredibly common
Why MannKind Stock Soared 19% Higher on Tuesday
05:16pm, Tuesday, 08'th Aug 2023
There's nothing like an estimate-topping quarter to put some pep in a company. A big jump in royalty revenue was particularly notable.
